Cellular Adhesion Molecule
Introduction
Cellular adhesion molecules (CAMs) are a diverse group of proteins located on the cell surface that play a fundamental role in mediating cell-to-cell and cell-to-extracellular matrix interactions. These interactions are vital for maintaining tissue structure, facilitating cellular communication, and coordinating various biological processes, including immune responses, inflammation, and tissue development. [1]
Biological Basis
Among the most well-studied CAMs is Intercellular Adhesion Molecule-1 (ICAM-1), also known as CD54. ICAM-1 belongs to the immunoglobulin superfamily and is primarily recognized for its role in the immune system. It acts as a ligand for integrins, such as Mac-1 (CD11b/CD18), found on the surface of leukocytes. The binding between ICAM-1 and these integrins is a critical step in leukocyte extravasation, allowing immune cells to move from the bloodstream into tissues at sites of inflammation or infection. [2]
The ICAM-1 gene is located on chromosome 19p13.2, and its expression and circulating levels of its soluble form (s_ICAM-1_) are subject to genetic influences. [3] For instance, specific polymorphisms within the ICAM-1 gene, such as the Gly241Arg variant, have been linked to variations in serum s_ICAM-1_ concentrations. [4] Beyond direct gene variants, broader genetic factors can also impact s_ICAM-1_ levels. Notably, a significant association has been identified between the ABO histo-blood group antigen and soluble ICAM-1 levels. [3] The ABO gene encodes glycosyltransferase enzymes that add specific sugar residues to cell surface antigens. Differences in these enzymes, dictated by ABO alleles (A, B, or O), can influence the glycosylation patterns of proteins, including ICAM-1, which in turn can affect its binding capabilities and signaling activities. [2]
Clinical Relevance
Dysregulation of CAMs, particularly s_ICAM-1_, is implicated in the pathogenesis of numerous diseases. Elevated plasma concentrations of s_ICAM-1_ have been identified as a risk factor for future myocardial infarction in apparently healthy individuals. [5] Similarly, increased levels of s_ICAM-1_ and soluble vascular adhesion molecule-1 (s_VCAM-1_) are associated with the development of symptomatic peripheral arterial disease. [6] Circulating levels of these endothelial adhesion molecules also show an association with the risk of diabetes. [7] The involvement of ICAM-1 extends to chronic inflammatory conditions like atherosclerosis [8] and it has been associated with type 1 diabetes. [9] Furthermore, ICAM-1 plays a role in infectious diseases; a soluble form can inhibit rhinovirus infection [10] while Plasmodium falciparum-infected erythrocytes utilize ICAM-1 as a binding target, a mechanism linked to cerebral malaria. [11]
Social Importance
The widespread involvement of cellular adhesion molecules in health and disease underscores their social importance. Understanding the genetic and environmental factors that modulate CAM function and soluble levels provides crucial insights for risk assessment, early diagnosis, and the development of targeted therapeutic strategies for prevalent conditions such as cardiovascular diseases, diabetes, and inflammatory disorders. The discovery of associations between common genetic variations, like ABO blood groups, and ICAM-1 levels highlights the intricate interplay between our genetic makeup and disease susceptibility, offering pathways for personalized medicine approaches that can ultimately improve public health outcomes globally.
Methodological and Statistical Considerations
Genome-wide association studies (GWAS) inherently face challenges related to study design, statistical power, and the extensive multiple testing burden. While many studies involve thousands of participants [3], [12], [13] the power to detect modest genetic effects remains a limitation, particularly when adhering to stringent genome-wide significance thresholds. [14] Conservative statistical approaches, such as Bonferroni correction, can lead to a high rate of false negatives, potentially obscuring true associations with smaller effect sizes . [15], [16]
A critical limitation for initial GWAS findings is the frequent necessity for independent replication in diverse cohorts to confirm associations. [17] Non-replication can stem from differences in study power, design, or insufficient coverage of genetic variation across different SNP arrays . [14], [18] Moreover, the failure to replicate an association at a specific SNP does not definitively rule out a true genetic link, as different SNPs within the same gene or region might be in strong linkage disequilibrium with an unobserved causal variant in various populations. [18]
Generalizability and Phenotypic Characterization
Many genetic studies, despite employing methods to correct for population stratification [19], [20] are predominantly conducted within populations of specific ancestries, such as those of European descent . [13], [21] This focus can restrict the generalizability of findings to more ethnically diverse populations, where genetic architectures, allele frequencies, or environmental exposures may differ . [7], [22] Although some analyses exclude individuals not clustering with the primary ethnic group [13] residual stratification could still subtly influence results, necessitating careful interpretation of cross-population applicability.
The precision and comprehensiveness of phenotypic measurements are also significant considerations. For cellular adhesion molecule studies, the variability of serum soluble ICAM-1 levels can be attributed to common polymorphisms, which may impact the accuracy and consistency of the phenotype. [23] Furthermore, the SNP arrays utilized in earlier GWAS, such as the Affymetrix 100K chip, provided only partial coverage of the human genome . [16], [24] This limited coverage means that some causal variants or genes might have been missed due to inadequate representation, and comprehensive investigation of candidate genes often requires denser arrays or targeted sequencing . [16], [24]
Unexplored Genetic and Environmental Influences
Genetic associations for complex traits are frequently modulated by environmental factors, leading to context-specific effects. [14] Interactions between genes and environmental exposures, such as dietary intake, can significantly influence phenotypic expression, yet many GWAS do not explicitly investigate these intricate gene-environment interactions. [14] The contribution of shared family environment and other unshared non-familial factors can also account for a portion of trait variance, making it challenging to isolate purely genetic effects. [25]
Despite the identification of significant genetic loci, a substantial proportion of the heritability for many complex traits often remains unexplained, a phenomenon referred to as "missing heritability". [12] This gap may be attributed to undetected genetic variants with very small effect sizes, rare variants, structural variations like copy number variants [15] or complex epistatic interactions not captured by standard analyses. Moreover, many studies, by pooling sexes to enhance statistical power, may overlook sex-specific genetic associations that manifest uniquely in males or females [24] highlighting areas for future research into specific biological mechanisms and their context-dependent roles.
Variants
The gene MIR3171HG is a long non-coding RNA (lncRNA) that hosts miR-3171, a microRNA. LncRNAs are a diverse class of RNA molecules over 200 nucleotides in length that do not code for proteins but play crucial roles in regulating gene expression at various levels, including transcriptional, post-transcriptional, and epigenetic mechanisms. [17] MicroRNAs, like miR-3171, are small non-coding RNAs that typically silence gene expression by binding to complementary sequences on target messenger RNAs (mRNAs), leading to mRNA degradation or inhibition of protein synthesis. [24] Together, MIR3171HG and miR-3171 contribute to a complex regulatory network that can influence a wide array of biological processes within cells.
The regulatory functions of MIR3171HG and miR-3171 are particularly relevant to cellular adhesion, a fundamental process involving specialized proteins that mediate cell-to-cell and cell-to-extracellular matrix interactions. These interactions are critical for tissue development, immune responses, and disease progression, such as inflammation and cancer metastasis. [3] For instance, MIR3171HG could act as a molecular sponge, sequestering other microRNAs that would otherwise target messenger RNAs encoding cellular adhesion molecules (CAMs) like ICAM-1, thereby indirectly promoting their expression. Conversely, miR-3171 might directly target and downregulate specific CAM mRNAs, altering the cell's adhesive properties. [15] Such precise regulation is vital for maintaining cellular homeostasis and responding to environmental cues.
The single nucleotide polymorphism (SNP) rs17112580 is a genetic variation located within the MIR3171HG locus. Depending on its exact position, this SNP could influence the transcription, processing, or stability of the MIR3171HG lncRNA, or even affect the maturation or activity of its hosted microRNA, miR-3171. [26] Changes induced by rs17112580 could lead to altered levels or functions of MIR3171HG or miR-3171, subsequently disrupting the delicate balance of gene expression for cellular adhesion molecules. This genetic variation might therefore contribute to individual differences in traits related to cellular adhesion, inflammation, or immune responses, impacting susceptibility to various diseases. [25]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs17112580 | MIR3171HG | cellular adhesion molecule measurement |
Defining Cellular Adhesion Molecules and Soluble Forms
Cellular adhesion molecules (CAMs) are a diverse group of proteins expressed on the cell surface that facilitate cell-cell and cell-extracellular matrix interactions, which are fundamental to various biological processes such as immune surveillance, tissue development, and inflammatory responses. A key example is Intercellular Adhesion Molecule-1 (ICAM-1), a transmembrane glycoprotein critical for leukocyte adhesion and transendothelial migration during inflammation. Its expression on endothelial cells is significantly increased by inflammatory cytokines, underscoring its pivotal role in mediating immune cell trafficking. [27] The detection of circulating soluble ICAM-1 (s_ICAM-1_) in plasma or serum provides an operational definition and measurement approach for systemic inflammation and endothelial dysfunction, serving as a valuable biomarker in clinical and research settings.
The presence of s_ICAM-1_ is particularly relevant as its levels are associated with various pathological conditions, including the development of symptomatic peripheral arterial disease [6] and an increased risk of diabetes. [7] Elevated plasma concentrations of s_ICAM-1_ have also been linked to a higher risk of future myocardial infarction in seemingly healthy men [5] highlighting its significance as a prognostic indicator for cardiovascular events. This soluble form arises from shedding of the cell-surface molecule, making its quantification a critical measurement approach for assessing disease progression and inflammatory burden.
Classification and Key Terminology
Cellular adhesion molecules are broadly classified into several families, including selectins, integrins, cadherins, and the immunoglobulin superfamily, with ICAM-1 belonging to the latter. ICAM-1 is also known by the standardized nomenclature CD54, reflecting its specific cluster of differentiation designation. [2] Related concepts include other "endothelial adhesion molecules" such as Vascular Adhesion Molecule-1 (VCAM-1), which also plays a role in inflammatory processes and is often measured alongside s_ICAM-1_ to provide a broader assessment of endothelial activation. [6] The binding of ICAM-1 to integrins like Mac-1 (CD11b/CD18) on leukocytes is a well-defined interaction crucial for immune cell function. [2]
Genetic factors significantly influence the levels and function of these adhesion molecules, contributing to a deeper understanding of their classification and clinical impact. For instance, circulating s_ICAM-1_ levels show linkage to the ICAM gene cluster region on chromosome 19 [28] indicating a genetic predisposition to variations in its concentration. Furthermore, specific gene polymorphisms, such as the Gly241Arg ICAM-1 gene polymorphism, have been associated with serum s_ICAM-1_ concentrations. [4] A novel association has also been identified between the ABO histo-blood group antigen and soluble ICAM-1 levels [3] adding another layer to the complex genetic framework influencing these critical molecules.
Measurement Approaches and Diagnostic Significance
The measurement of circulating adhesion molecules like s_ICAM-1_ is typically performed using highly sensitive immunoassays, such as immunoenzymometric assays, similar to those employed for other inflammatory biomarkers like C-reactive protein (CRP). [18] These approaches quantify the concentration of the soluble protein in blood samples, providing a numerical value that can be used as a diagnostic or research criterion. The clinical criteria and research criteria for interpreting these measurements often involve establishing thresholds or cut-off values that indicate elevated risk for specific conditions. For example, higher levels of s_ICAM-1_ are considered biomarkers for increased risk of atherosclerosis [29] and may predict the progression of cardiovascular disease.
These measurement approaches are crucial for identifying individuals at risk and for monitoring disease activity. The utility of s_ICAM-1_ as a biomarker is further enhanced by its association with genetic variations that modulate its levels, such as those within the ICAM gene cluster [28] or specific single nucleotide polymorphisms (SNPs). [4] Such genetic insights can refine risk stratification and contribute to a more personalized approach to diagnostic assessment. The integration of biomarker levels with genetic information represents a comprehensive conceptual framework for understanding the role of cellular adhesion molecules in health and disease.
Intercellular Adhesion Molecule-1: Structure and Fundamental Role
Intercellular Adhesion Molecule-1 (ICAM-1), also known as CD54, is a critical cell surface glycoprotein belonging to the immunoglobulin superfamily of adhesion receptors. This molecule features five immunoglobulin-like extracellular domains, a transmembrane domain, and a short cytoplasmic domain, which together enable its diverse cellular functions. [1] Primarily expressed on endothelial cells, ICAM-1 acts as a receptor for specific leukocyte integrins, such as LFA-1 (lymphocyte function-associated antigen-1) and Mac-1 (CD11b/CD18), thereby facilitating the adhesion of immune cells and their subsequent migration across the endothelial barrier during inflammatory responses. [1] A soluble form of ICAM-1 (s_ICAM-1_), consisting solely of the extracellular domains, circulates in the plasma and is believed to modulate inflammatory and immune processes by potentially interfering with cell-surface ICAM-1 interactions. [3]
The interaction between ICAM-1 and its integrin partners, particularly Mac-1, is highly specific, with Mac-1 binding to the third immunoglobulin-like domain of ICAM-1. [2] This binding is crucial for mediating various cellular functions, including immune cell trafficking and pathogen recognition. Beyond its role in direct cell-to-cell adhesion, ICAM-1 can also initiate intracellular signaling pathways upon ligand binding, influencing cellular responses and gene expression patterns in endothelial cells and leukocytes. [27] The precise mechanisms governing the formation and release of s_ICAM-1_ into circulation are not fully elucidated, but its presence suggests a regulatory role in systemic inflammation and immune modulation.
Genetic Determinants and Expression Regulation of ICAM-1
The expression of ICAM-1 is tightly regulated at the genetic level, with its gene located within a cluster on chromosome 19. [28] Genetic variations, such as single nucleotide polymorphisms (SNPs), within the ICAM-1 gene or its regulatory regions can influence both the baseline and induced levels of ICAM-1 and s_ICAM-1_. [4] For instance, a quantitative trait locus (QTL) on chromosome 19 has been identified that influences circulating levels of ICAM-1. [22] Furthermore, the transcriptional regulation of the ICAM-1 gene is significantly responsive to inflammatory cytokines in human endothelial cells, involving key regulatory elements like a variant NF-kappa B site and p65 homodimers, which drive its upregulation during inflammation. [27]
Recent genome-wide association studies have revealed novel genetic associations that impact ICAM-1 levels, including a notable link between the ABO histo-blood group antigen and soluble ICAM-1. [3] The ABO blood group system, characterized by specific glycosyltransferases, influences the glycosylation patterns on various plasma proteins, including alpha 2-macroglobulin and von Willebrand factor. [30] This suggests a potential indirect mechanism where ABO genotype, through its influence on glycosylation, may affect the stability, release, or signaling properties of ICAM-1 or its interacting partners, thereby modulating s_ICAM-1_ concentrations in circulation.
ICAM-1 in Immune and Inflammatory Pathways
ICAM-1 plays a pivotal role in mediating immune responses and inflammatory processes by facilitating the recruitment and extravasation of leukocytes to sites of inflammation. [1] Its upregulation on endothelial cells, often triggered by inflammatory cytokines, enhances the adhesion of lymphocytes and other immune cells, which is a critical step in initiating and sustaining an immune response. [31] The dynamic interaction between ICAM-1 and integrins on leukocytes enables precise control over immune cell migration, ensuring that immune cells can effectively reach affected tissues. In particular, thrombin, a key enzyme in coagulation, has been shown to upregulate ICAM-1 expression in human monocytes and THP-1 cells, linking coagulation pathways with inflammatory responses. [32]
Beyond its role in host immunity, ICAM-1 also serves as a receptor for various pathogens, highlighting its dual nature in health and disease. For instance, it is a crucial receptor for human rhinovirus, and its soluble form can inhibit viral infection. [10] Moreover, Plasmodium falciparum-infected erythrocytes bind to ICAM-1 at a specific site distinct from its leukocyte binding domains, a interaction implicated in the pathogenesis of cerebral malaria. [11] This demonstrates how pathogens exploit host adhesion molecules to establish infection and contribute to disease progression.
Pathophysiological Relevance of ICAM-1 and Soluble Forms
Elevated circulating levels of s_ICAM-1_ are recognized as a biomarker for various pathophysiological conditions, reflecting endothelial activation and systemic inflammation. [5] High plasma concentrations of s_ICAM-1_ have been associated with an increased risk of future myocardial infarction and the development of symptomatic peripheral arterial disease. [5] In the context of atherosclerosis, s_ICAM-1_ appears to have a differential effect on disease progression compared to arterial thrombosis, underscoring the complex interplay of adhesion molecules in cardiovascular health. [29] The involvement of ICAM-1 in inflammation, a known driver of atherosclerosis, highlights its role in the initiation and progression of vascular diseases. [8]
Furthermore, ICAM-1 and its soluble forms are implicated in metabolic disorders, with circulating levels of endothelial adhesion molecules being linked to the risk of diabetes. [7] Genetic variations within the ICAM-1 gene have also been associated with conditions such as type 1 diabetes. [9] In neurological contexts, soluble ICAM-1 has been shown to block lymphocyte attachment to cerebral endothelial cells, suggesting a role in modulating neuroinflammation. [33] These diverse associations underscore ICAM-1's broad impact on homeostatic disruptions and disease mechanisms across multiple organ systems.
Post-Translational Modifications and Intermolecular Interactions
The function of ICAM-1 is not solely determined by its primary protein sequence but is also significantly influenced by post-translational modifications, particularly glycosylation. The presence of sialylated complex-type N-glycans on soluble ICAM-1 has been shown to enhance its signaling activity in mouse astrocytes, indicating that specific carbohydrate structures can modulate its biological effects. [23] This intricate glycosylation pattern can affect ICAM-1's ability to bind ligands, its stability, and its subsequent signaling cascades.
Moreover, the ABO histo-blood group antigens, which are carbohydrate structures, are covalently linked to various plasma proteins like alpha 2-macroglobulin and von Willebrand factor in an ABO phenotype-dependent manner. [30] While ICAM-1 itself is not directly stated to carry ABO antigens in the provided context, the known influence of ABO on circulating proteins suggests potential indirect mechanisms where ABO status could affect the overall glycosylation environment or the interaction with other glycosylated molecules that in turn impact ICAM-1 function or s_ICAM-1_ levels. Such molecular interactions and modifications are critical for fine-tuning ICAM-1's roles in cellular adhesion, immune response, and disease pathogenesis.
Receptor-Mediated Signaling and Intracellular Cascades
Cellular adhesion molecules, such as ICAM-1, initiate complex intracellular signaling cascades upon ligand binding, crucial for regulating cellular responses. The binding of ICAM-1 to its primary ligand, the integrin Mac-1 (CD11b/CD18), triggers downstream events that modulate cell adhesion, migration, and immune cell activation. [2] This receptor activation propagates signals through various intracellular pathways, influencing cytoskeletal rearrangements and gene expression. Furthermore, soluble forms of ICAM-1 can also possess signaling activity, which is notably enhanced by specific post-translational modifications, indicating a sophisticated regulatory network. [23]
Inflammatory mediators play a significant role in modulating the signaling pathways associated with ICAM-1. For instance, inflammatory cytokines transcriptionally regulate the ICAM-1 gene, involving critical transcription factors like NF-kappa B and its p65 homodimers. [27] Similarly, thrombin has been shown to upregulate ICAM-1 expression in human monocytes, demonstrating how external stimuli feed into these signaling cascades to alter adhesion molecule presentation and function [32] These intricate signaling pathways ensure that ICAM-1 expression and activity are finely tuned to cellular needs and environmental cues, particularly in inflammatory contexts.
Post-Translational Regulation and Glycosylation
The functional activity of cellular adhesion molecules is profoundly influenced by post-translational modifications, with glycosylation being a key regulatory mechanism. For ICAM-1, the presence of sialylated complex-type N-glycans has been shown to enhance its signaling activity, especially for its soluble form. [23] This modification can alter protein conformation, stability, and interaction with other molecules, thereby modulating its adhesive and signaling capabilities. The binding of ICAM-1 to integrins like Mac-1 is also regulated by glycosylation, highlighting its direct impact on receptor-ligand interactions. [2]
Beyond direct modification of ICAM-1, broader glycosylation pathways can have systemic effects relevant to adhesion molecules. The ABO(H) blood group antigens, which are carbohydrate structures, are covalently linked to other human plasma proteins such as alpha 2-macroglobulin and von Willebrand factor. [30] This suggests a potential interplay between an individual's ABO phenotype, the overall glycosylation landscape, and the functional properties of circulating adhesion molecules or their interacting partners, contributing to diverse biological outcomes.
Transcriptional Control and Genetic Influences
The expression levels of cellular adhesion molecules are under stringent transcriptional control, dictated by a complex interplay of genetic factors and environmental signals. The ICAM-1 gene, for instance, is transcriptionally regulated by inflammatory cytokines, with specific regulatory elements like a variant NF-kappa B site and p65 homodimers playing essential roles. [27] This precise control ensures that ICAM-1 is upregulated in response to inflammatory conditions, facilitating immune cell recruitment.
Genetic polymorphisms significantly contribute to the variability in circulating levels of adhesion molecules. A common nonsynonymous variant in the ICAM-1 gene, Gly241Arg, is associated with serum soluble ICAM-1 concentration. [4] Furthermore, genome-wide association studies have identified linkage to the ICAM gene cluster region on chromosome 19 as a determinant of circulating soluble ICAM-1 levels. [28] Intriguingly, the ABO histo-blood group antigen gene has also been associated with soluble ICAM-1 levels, indicating a broader genetic landscape influencing the availability and function of these critical molecules. [3]
Inter-Pathway Crosstalk and Disease Relevance
Cellular adhesion molecules are integral components of complex biological networks, exhibiting extensive crosstalk with various other pathways and playing critical roles in disease pathophysiology. Dysregulation of ICAM-1 expression or its soluble forms is implicated in numerous diseases, including atherosclerosis, peripheral arterial disease, type 1 diabetes, and an increased risk of future myocardial infarction. [8] In atherosclerosis, for example, ICAM-1 promotes leukocyte adhesion to the endothelium, contributing to plaque formation and progression. [29]
The functional significance of ICAM-1 extends to host-pathogen interactions and immune responses. It serves as a binding site for Plasmodium falciparum-infected erythrocytes, which is distinct from its binding sites for LFA-1, Mac-1, and human rhinovirus. [11] Conversely, a soluble form of ICAM-1 has been shown to inhibit rhinovirus infection, highlighting its emergent properties in modulating infectious disease outcomes. [10] These multifaceted roles underscore the importance of understanding the intricate interactions of adhesion molecules within broader biological systems for developing targeted therapeutic strategies.
Clinical Relevance
Cellular adhesion molecules, particularly intercellular adhesion molecule-1 (ICAM-1), play critical roles in various physiological and pathological processes, including inflammation, immune responses, and vascular health. Soluble forms of ICAM-1 (sICAM-1) circulating in plasma are emerging as important biomarkers with significant clinical relevance for diagnosis, prognosis, and risk stratification across several disease states.
Prognostic and Diagnostic Utility in Cardiovascular Disease
Elevated levels of soluble ICAM-1 (sICAM-1) have demonstrated significant prognostic value in assessing cardiovascular risk. Studies indicate that higher plasma concentrations of sICAM-1 are associated with an increased risk of future myocardial infarction in apparently healthy men. [5] Furthermore, sICAM-1 levels are linked to the development of symptomatic peripheral arterial disease (PAD) [6] and serve as a predictor for the progression of peripheral atherosclerosis in the general population. [34] An early increase in sICAM-1 levels can also be a potential risk factor for acute coronary syndromes [35] suggesting its utility in identifying individuals at high risk for acute cardiac events. The differential effects of sICAM-1 on atherosclerosis progression versus arterial thrombosis , with a quantitative trait locus (QTL) for sICAM-1 levels mapped to this region in certain populations. [22] Specific gene polymorphisms, such as the Gly241Arg variant in the ICAM-1 gene, are associated with variations in serum sICAM-1 concentration. [4] A genome-wide association study (GWAS) further revealed a novel association between the ABO histo-blood group antigen and sICAM-1 levels. [36] Given that ABO blood groups are known to influence plasma von Willebrand factor levels and are associated with vascular disease [37] these genetic insights could facilitate personalized risk stratification for cardiovascular and other related conditions. Identifying individuals with specific genetic profiles influencing sICAM-1 levels may enable targeted prevention strategies and earlier clinical interventions.
Adhesion Molecules in Inflammatory and Metabolic Conditions
Beyond cardiovascular disease, ICAM-1 and its soluble forms are implicated in a broader range of inflammatory and metabolic conditions. Elevated circulating levels of endothelial adhesion molecules, including sICAM-1, are associated with an increased risk of developing diabetes in ethnically diverse cohorts. [7] Additionally, genetic associations between the ICAM-1 gene and type 1 diabetes have been reported. [9] ICAM-1 plays a fundamental role in inflammatory processes, with its expression being transcriptionally regulated by inflammatory cytokines [27] and upregulated by thrombin in various cell types. [32] Furthermore, ICAM-1 is critical in host-pathogen interactions, serving as a binding site for Plasmodium falciparum-infected erythrocytes [11] and demonstrating an ability to inhibit rhinovirus infection. [10] These diverse associations highlight ICAM-1's potential as a biomarker and a therapeutic target across a spectrum of inflammatory, metabolic, and infectious diseases, suggesting its broad clinical utility.
References
[1] van de Stolpe, A, and PT van der Saag. "Intercellular adhesion molecule-1." J Mol Med, vol. 74, 1996, pp. 13–33.
[2] Diamond, M. S., et al. "Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation." Cell, vol. 65, 1991, pp. 961–971.
[3] Pare, G, et al. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 4, no. 7, 2008, pp. e1000118.
[4] Ponthieux, A, et al. "Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort." Eur J Hum Genet, vol. 11, 2003, pp. 679–686.
[5] Ridker, P. M., et al. "Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men." Lancet, vol. 351, 1998, pp. 88–92.
[6] Pradhan, A. D., et al. "Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men." Circulation, vol. 106, 2002, pp. 820–825.
[7] Song, Y, et al. "Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women." Diabetes, vol. 56, 2007, pp. 1898–1904.
[8] Libby, P, et al. "Inflammation and atherosclerosis." Circulation, vol. 105, 2002, pp. 1135–1143.
[9] Nejentsev, S, et al. "Association of intercellular adhesion molecule-1 gene with type 1 diabetes." Lancet, vol. 362, 2003, pp. 1723–1724.
[10] Marlin, S. D., et al. "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection." Nature, vol. 344, 1990, pp. 70–72.
[11] Ockenhouse, C. F., et al. "Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human rhinovirus." Cell, vol. 68, 1992, pp. 63–69.
[12] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, vol. 40, no. 12, 2008, pp. 1428–1437.
[13] Pare, G., et al. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genetics, vol. 5, no. 12, 2009, e1000762.
[14] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S2.
[15] Melzer, D., et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genetics, vol. 4, no. 5, 2008, e1000072.
[16] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S4.
[17] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S7.
[18] Sabatti, C. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet. 2008.
[19] Price, A. L., et al. "Discerning the ancestry of European Americans in genetic association studies." PLoS Genetics, vol. 4, no. 1, 2008, e1000010.
[20] Serre, D., et al. "Correction of population stratification in large multi-ethnic association studies." PLoS ONE, vol. 3, no. 9, 2008, e3124.
[21] Aulchenko, Y. S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nature Genetics, vol. 40, no. 12, 2008, pp. 1403–1411.
[22] Kent, J. W. Jr., et al. "Quantitative trait locus on Chromosome 19 for circulating levels of intercellular adhesion molecule-1 in Mexican Americans." Atherosclerosis, vol. 195, 2007, pp. 367–373.
[23] Otto, V. I., et al. "Sialylated complex-type N-glycans enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes." J Biol Chem, vol. 279, 2004, pp. 35201–35209.
[24] Yang, Q., et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S12.
[25] Wallace, C., et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139–149.
[26] Burkhardt, R., et al. "Common SNPs in HMGCR in Micronesians and Whites Associated with LDL-Cholesterol Levels Affect Alternative Splicing of Exon13." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 10, 2008, pp. 1858-65.
[27] Ledebur, H. C., and Parks, T. P. "Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers." J Biol Chem, vol. 270, 1995, pp. 933–943.
[28] Bielinski, S. J., et al. "Circulating soluble ICAM-1 levels shows linkage to ICAM gene cluster region on chromosome 19: The NHLBI Family Heart Study follow-up examination." Atherosclerosis, 2007.
[29] Albert, M. A., et al. "Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: A prospective analysis of the Women’s Health Study." Atherosclerosis, 2007.
[30] Matsui, T, et al. "Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype." Blood, vol. 82, 1993.
[31] Yang, Q, et al. "A key role for ICAM-1 in generating effector cells mediating inflammatory responses." Nat Immunol, vol. 2, 2001, pp. 523–529.
[32] Clark, P, et al. "Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo." Thromb Haemost, vol. 89, 2003, pp. 1043–1051.
[33] Rieckmann, P, et al. "Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells." J Neuroimmunol, vol. 60, 1995, pp. 9–15.
[34] Tzoulaki, I., et al. "C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study." Circulation, vol. 112, 2005, pp. 976–983.
[35] O’Malley, T., et al. "Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes." Eur Heart J, vol. 22, 2001, pp. 1226–1234.
[36] Pare, G., et al. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 3, no. 7, 2007.
[37] Jenkins, P. V., and O’Donnell, J. S. "ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?" Transfusion, vol. 46, 2006, pp. 1836–1844.